EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Hemosphere, Inc., a leading innovator of vascular access technologies, announced today that the HeRO Graft was recently recognized by the Premier healthcare alliance as part of a national program focusing on innovation and performance improvement in healthcare.
The HeRO Graft was one of 18 medical innovations on display at Premier’s third annual Innovation Celebration in Nashville, Tennessee, which celebrated advances in healthcare while highlighting healthcare industry suppliers committed to innovation and improving patient outcomes. The product was selected by a committee of clinicians and other Premier alliance members based on its ability to reduce costly infections and hospital re-admissions associated with end-stage renal disease access patients. Basic criteria for selection included solutions that displayed uniqueness, as well as those that have an impact on an unmet medical need.
“We are honored that Premier has recognized the HeRO Graft as an innovative medical technology which improves patient outcomes,” said Patrick Wethington, President and CEO of Hemosphere, Inc. “The HeRO Graft helps address the significant concerns that providers, clinicians and patients have related to costly infections and associated admissions-readmissions for the ESRD hemodialysis population with tunneled dialysis catheters.”
“These new devices and products have the potential to substantially impact the safety, quality and cost-effectiveness of care,” said Premier Purchasing Partners President Mike Alkire. “All of the Innovation Celebration participants share Premier’s commitment to provide innovative and valuable products and services to benefit our nation’s healthcare providers and the patients they serve.”
About Hemosphere, Inc.
Hemosphere, Inc., is leading innovation and collaboration in the global development and commercialization of technologies that revolutionize care and restore quality of life for end-stage renal disease patients with compromised vasculature.
The HeRO® Graft (Hemodialysis Reliable Outflow) is a unique AV access solution clinically proven to reduce costly infections by 69% compared to hemodialysis catheters. Over 3500 HeRO Grafts have been sold in the United States and clinical experience with HeRO has been presented in more than 70 publications, abstracts, and educational presentations.
For more information on Hemosphere, Inc. and the HeRO Graft, visit the company’s website at www.heroaccess.com
CONTACT:
Hemosphere, Inc.
Patrick J. Wethington
President and CEO
952-582-6900
KEYWORDS: United States North America Minnesota Tennessee
INDUSTRY KEYWORDS: Practice Management Health Biotechnology Cardiology Hospitals Infectious Diseases Medical Devices Manufacturing Engineering Medical Supplies Managed Care
MEDIA:
| Logo |